Litcius/Paper detail

Macrocyclic Peptides as a Novel Class of NNMT Inhibitors: A SAR Study Aimed at Inhibitory Activity in the Cell

Kyohei Hayashi, Shota Uehara, Shiho Yamamoto, Douglas R. Cary, Jun‐ichi Nishikawa, Taichi Ueda, Hiroki Ozasa, Kousuke Mihara, Norito Yoshimura, Taeko Kawai, Takashi Ono, Saki Yamamoto, Masataka Fumoto, Hidenori Mikamiyama

2021ACS Medicinal Chemistry Letters17 citationsDOIOpen Access PDF

Abstract

Nicotinamide N-methyltransferase (NNMT), which catalyzes the methylation of nicotinamide, is a cytosolic enzyme that has attracted much attention as a therapeutic target for a variety of diseases. However, despite the considerable interest in this target, reports of NNMT inhibitors have still been limited to date. In this work, utilizing in vitro translated macrocyclic peptide libraries, we identified peptide 1 as a novel class of NNMT inhibitors. Further exploration based on the X-ray cocrystal structures of the peptides with NNMT provided a dramatic improvement in inhibitory activity (peptide 23: IC50 = 0.15 nM). Furthermore, by balance of the peptides’ lipophilicity and biological activity, inhibitory activity against NNMT in cell-based assay was successfully achieved (peptide 26: cell-based IC50 = 770 nM). These findings illuminate the potential of cyclic peptides as a relatively new drug discovery modality even for intracellular targets.

Topics & Concepts

PeptideLipophilicityBiochemistryNicotinamideChemistryEnzymeInhibitory postsynaptic potentialStructure–activity relationshipIntracellularIn vitroBiologyNeuroscienceRNA and protein synthesis mechanismsBiochemical and Molecular ResearchSirtuins and Resveratrol in Medicine
Macrocyclic Peptides as a Novel Class of NNMT Inhibitors: A SAR Study Aimed at Inhibitory Activity in the Cell | Litcius